Nervous system: Peripheral nerve sheath tumors

2001-05-01   Fredrik Mertens , Ragnhild A. Lothe 

1.Dept of Clinical Genetics, Lund University Hospital, SE-221 85 Lund, Sweden



A peripheral nerve sheath tumor (PNST) is a neoplasm arising from a peripheral nerve or showing nerve sheath differentiation. PNSTs may be subdivided into benign and malignant (MPNST) variants. Several distinct benign subtypes have been recognized, including schwannoma (neurilemoma, neurinoma), neurofibroma, and perineurioma.

Clinics and Pathology


The etiology of PNSTs is usually unknown. However, several hereditary disorders are known to predispose to benign and malignant PNSTs, notably neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2), both of which are inherited in an autosomal dominant fashion. NF1 (also known as von Recklinghausen disease) is caused by mutations in the NF1 gene on chromosome 17 and is characterized by several phenotypic features including multiple neurofibromas and MPNSTs. The incidence of MPNST is in general rare, but half of all cases arise in NF1 patients. NF2, caused by muations in the NF2 gene on chromosome 22, predisposes to schwannomas, predominantly affecting the spine and the intracranial nerves.


All ages and both sexes may be affected by PNSTs. Sporadic MPNSTs are most common between 40 and 50 years of age, while those occurring in the setting of NF1 are diagnosed some 10 years earlier. In total, MPNSTs account for 5-10% of all soft tissue sarcomas.


  • Schwannomas are encapsulated spindle cell tumors with distinct Antoni A and B components, hyaline vessel walls, and nuclear palisading. Tumor cells are strongly immunopositive for the S-100 protein.
  • Neurofibromas are unencapsulated tumors composed of spindle cells dispersed in fibromyxoid stroma. The proportion of S-100 positive cells is variable.
  • Perineuriomas may arise in soft tissues or within nerves, and are composed of cells with elongated bipolar cytoplasmic processes frequently arranged in whorls or a storiform pattern. The neoplastic cells express vimentin and epithelial membrane antigen (EMA), but are negative for S-100 protein, desmin, muscle-specific actin, and CD34.
  • MPNSTs typically are characterized by the presence of pale spindle cells often arranged in fascicles with alternating cellular and more myxoid areas. The S-100 protein is expressed in 50-70% of the tumors, and the majority of cases are immunopositive for TP53.Most MPNSTs arise from Schwann cells, but the possibility remains that some arise from nerve sheath cells other than the Schwann cells, and approximately two-thirds of all MPNSTs are associated with neurofibromas.
  • Prognosis

    Benign PNSTs rarely recur after surgery. MPNST, on the other hand, is often a highly aggressive tumor, and more than 60% of the patients die of the disease.


    Cytogenetics morphological

  • Schwannomas : Approximately 75 cases with clonal chromosome aberrations have been reported. Irrespective of site of origin, these tumors almost always display a near-diploid karyotype, with loss of chromosome 22 material, either through loss of the entire chromosome 22 or through partial deletions of the long arm, as the most common (about half of the cases) abnormality. Other recurrent abnormalities include, in decreasing order of frequency, loss of a sex chromosome, -17, -15, and +7.
  • Neurofibromas : Only five cases with clonal chromosome abnormalities have been reported, and no recurrent abnormality has been detected among them. All had, however, near-diploid karyotypes, and one case displayed monosomy 22.
  • Perineuriomas : There is a dearth of information on perineuriomas, but from the few cases that have been analyzed, it seems as if loss of chromosome 22 sequences is a prominent feature, indicating that they are pathogenetically related to schwannomas.
  • MPNSTs : Less than 75 cases with clonal chromosome aberration have been reported. The majority of cases displays complex karyotypes, often with a chromosome number in the tripolid or tetraploid range. No specific balanced rearrangement has been detected among them. Frequently involved breakpoints (at least 10% of the cases) include 1p11, 5p15, 7p22, 9p11, 11q13, 17p11, 17q11, 17q21, 20q13, and 22q11. Frequent (at least 20% of the cases) chromosomal imbalances include loss of 1p21-p36, 3p21-p23, 5p15, 6q23-q27, 7p22, 9p12-p24, 10p, 11p, 11q13-q25, 12p13, 12q22-q24, 13p, 15p, chromosomes 16 and 17, 19p, 20q13, and chromosomes 22 and X, and gain of chromosome 7. No clear difference in karyotypic profile between sporadic cases and NF1-associated MPNSTs has been detected.

    Cytogenetic-morphologic correlations
    Schwannoma : No association between karyotypic features and patient age, tumor size, or site of tumor origin has been detected.
    MPNST : Preliminary data indicate that the presence of a triploid or tetraploid clone is associated with large-sized tumors, high-grade tumors, and shorter overall survival.

  • Cytogenetics molecular

  • Schwannoma : Comparative genomic hybridization (CGH) analysis of a limited number of sporadic and NF2-associated schwannomas has shown that loss of 22q sequences is the most frequent imbalance.
  • MPNST : About 50 cases have been investigated by CGH. In contrast to the imbalance maps derived from cytogenetic analyses, the CGH data indicate that gain of distal 17q and loss of 13q14-q21 are frequent (approximately half of the cases) in MPNST. Additional frequent changes reported are gain of 5p, 7, 8q and loss of 9p sequences.
  • Cytogenetics morphological

    Molecular cytogenetic - clinical correlation MPNST: One study has reported poor overall patient survival associated with simultaneous gain of 17q and 7p.

    Genes Involved and Proteins


    Molecular genetic findings
    Schwannoma : The frequent finding of deletions at 22q suggests that this chromosome arm harbors one or more tumor suppressor loci of importance for schwannoma development. Focussing on the NF2 locus, loss of this tumor suppressor gene has been demonstrated in one third to half of all schwannomas investigated. The importance of this gene in schwannomas is further supported by the finding of biallelic inactivating mutations in up to two thirds of the cases.
    Neurofibroma : Biallelic inactivation of the NF1 gene in 17q has been demonstrated.
    MPNST : The basis for MPNST occurring in the setting of NF1 is presumed to be biallelic inactivation of the NF1 gene. Indeed, allelic imbalance at the NF1 locus in 17q is commonly (20-50% of the cases) detected in sporadic as well as NF1-associated MPNSTs. Due to the large size of this gene, however, it has been difficult to identify the mutation in the non-deleted copy in but a few cases. From studies of neurofibromas in NF1 patients, showing frequent deletion of the wild-type allele, it is obvious that NF1 inactivation is not sufficient for malignant transformation. Molecular genetic investigations aiming at disclosing mechanisms of importance for tumor progression have revealed that MPNSTs often display disruption of the RB1 pathway. Thus, the CDKN2A locus in 9p21 often displays loss of heterozygosity, and the gene itself is homozygously deleted or otherwise rendered functionally inactive. Also the CDKN2B and RB1 tumor suppressor genes may be inactivated in a subset of MPNSTs. Alternatively, dominantly acting genes in the RB1 pathway ­ CDK4, MDM2, and CCND2 ­ may be overexpressed or amplified. In a study of 12 MPNSTs, changes in one or more of these dominantly or recessively acting genes were found in 11 cases. The TP53 gene, on the other hand, seems to be biallelically affected in only a small proportion of MPNSTs.


    Pubmed IDLast YearTitleAuthors
    111295302000Genetic aberrations in sporadic and neurofibromatosis 2 (NF2)-associated schwannomas studied by comparative genomic hybridization (CGH).Antinheimo J et al
    104694531999Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: studies of CDKN2A and other genes of the pRB pathway.Berner JM et al
    105916521999Mouse models of tumor development in neurofibromatosis type 1.Cichowski K et al
    103628101999Correlation between clinicopathological features and karyotype in spindle cell sarcomas. A report of 130 cases from the CHAMP study group.Fletcher CD et al
    88895061996Frequency and distribution of NF2 mutations in schwannomas.Jacoby LB et al
    88409981996Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis.Lothe RA et al
    78150811995Alterations at chromosome 17 loci in peripheral nerve sheath tumors.Lothe RA et al
    111354382001Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors.Lothe RA et al
    103984301999Analysis of chromosomal imbalances in sporadic and NF1-associated peripheral nerve sheath tumors by comparative genomic hybridization.Mechtersheimer G et al
    106409892000Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group.Mertens F et al
    103798661999Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant.Schmidt H et al
    93263161997Confirmation of a double-hit model for the NF1 gene in benign neurofibromas.Serra E et al
    25772711989Molecular genetic analysis of tumors in von Recklinghausen neurofibromatosis: loss of heterozygosity for chromosome 17.Skuse GR et al
    105916531999Mouse tumor model for neurofibromatosis type 1.Vogel KS et al


    Fredrik Mertens ; Ragnhild A. Lothe

    Nervous system: Peripheral nerve sheath tumors

    Atlas Genet Cytogenet Oncol Haematol. 2001-05-01

    Online version: